Literature DB >> 15836544

Ambulatory hypercholesterolemia management in patients with atherosclerosis. Gender and race differences in processes and outcomes.

Stephen D Persell1, Saverio M Maviglia, David W Bates, John Z Ayanian.   

Abstract

OBJECTIVE: To determine whether outpatient cholesterol management varies by gender or race among patients with atherosclerosis, and assess factors related to subsequent cholesterol control.
DESIGN: Retrospective cohort study.
SETTING: Primary care clinics affiliated with an academic medical center. PARTICIPANTS: Two hundred forty-three patients with coronary heart disease, cerebrovascular disease, or peripheral vascular disease and low-density lipoprotein cholesterol (LDL-C)>130 mg/dl.
MEASUREMENTS AND MAIN RESULTS: The primary process of care assessed for 1,082 office visits was cholesterol management (medication intensification or LDL-C monitoring). Cholesterol management occurred at 31.2% of women's and 38.5% of men's visits (P=.01), and 37.3% of black and 31.7% of white patients' visits (P=.09). Independent predictors of cholesterol management included female gender (adjusted risk ratio [ARR], 0.77; 95% confidence interval [CI], 0.60 to 0.97), seeing a primary care clinician other than the patient's primary care physician (ARR, 0.23; 95% CI, 0.11 to 0.45), and having a new clinical problem addressed (ARR, 0.60; 95% CI, 0.48 to 0.74). After 1 year, LDL-C <130 mg/dl occurred less often for women than men (41% vs 61%; P=.003), black than white patients (39% vs 58%; P=.01), and patients with only Medicare insurance than with commercial insurance (37% vs 58%; P=.008). Adjustment for clinical characteristics and management attenuated the relationship between achieving an LDL-C <130 mg/dl and gender.
CONCLUSIONS: In this high-risk population with uncontrolled cholesterol, cholesterol management was less intensive for women than men but similar for black and white patients. Less intense cholesterol management accounted for some of the disparity in cholesterol control between women and men but not between black and white patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15836544      PMCID: PMC1490051          DOI: 10.1111/j.1525-1497.2005.40155.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  48 in total

1.  Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey.

Authors:  A I Qureshi; M F Suri; L R Guterman; L N Hopkins
Journal:  Arch Intern Med       Date:  2001-07-09

2.  Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease.

Authors:  T H Lee; J I Cleeman; S M Grundy; C Gillett; R C Pasternak; J Seidman; C Sennett
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

3.  Use of cholesterol-lowering therapy and related beliefs among middle-aged adults after myocardial infarction.

Authors:  John Z Ayanian; Bruce E Landon; Mary Beth Landrum; James R Grana; Barbara J McNeil
Journal:  J Gen Intern Med       Date:  2002-02       Impact factor: 5.128

4.  Using an electronic medical record to identify opportunities to improve compliance with cholesterol guidelines.

Authors:  S M Maviglia; J M Teich; J Fiskio; D W Bates
Journal:  J Gen Intern Med       Date:  2001-08       Impact factor: 5.128

5.  Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease.

Authors:  A D Federman; A S Adams; D Ross-Degnan; S B Soumerai; J Z Ayanian
Journal:  JAMA       Date:  2001-10-10       Impact factor: 56.272

6.  Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3.

Authors:  G C Fonarow; W J French; L S Parsons; H Sun; J A Malmgren
Journal:  Circulation       Date:  2001-01-02       Impact factor: 29.690

7.  Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators.

Authors:  M Miller; R Byington; D Hunninghake; B Pitt; C D Furberg
Journal:  Arch Intern Med       Date:  2000-02-14

Review 8.  Race and sex differences in the management of coronary artery disease.

Authors:  S E Sheifer; J J Escarce; K A Schulman
Journal:  Am Heart J       Date:  2000-05       Impact factor: 4.749

9.  Impact of availability of hospital-based invasive cardiac services on racial differences in the use of these services.

Authors:  P M Gregory; G G Rhoads; A C Wilson; K J O'Dowd; J B Kostis
Journal:  Am Heart J       Date:  1999-09       Impact factor: 4.749

10.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Authors:  T A Pearson; I Laurora; H Chu; S Kafonek
Journal:  Arch Intern Med       Date:  2000-02-28
View more
  6 in total

Review 1.  Cardiovascular health disparities: a systematic review of health care interventions.

Authors:  Andrew M Davis; Lisa M Vinci; Tochi M Okwuosa; Ayana R Chase; Elbert S Huang
Journal:  Med Care Res Rev       Date:  2007-10       Impact factor: 3.929

Review 2.  Disparities in vascular surgery: is it biology or environment?

Authors:  Louis L Nguyen; Antonia J Henry
Journal:  J Vasc Surg       Date:  2010-04       Impact factor: 4.268

3.  Race-sex differences in the management of hyperlipidemia: the REasons for Geographic and Racial Differences in Stroke study.

Authors:  Monika M Safford; Christopher M Gamboa; Raegan W Durant; Todd M Brown; Stephen P Glasser; James M Shikany; Richard M Zweifler; George Howard; Paul Muntner
Journal:  Am J Prev Med       Date:  2015-05       Impact factor: 5.043

4.  A retrospective cohort study of the potency of lipid-lowering therapy and race-gender differences in LDL cholesterol control.

Authors:  Barbara J Turner; Christopher S Hollenbeak; Mark Weiner; Simon S K Tang
Journal:  BMC Cardiovasc Disord       Date:  2011-09-30       Impact factor: 2.298

5.  Gender differences in aspirin use among adults with coronary heart disease in the United States.

Authors:  Alexander R Opotowsky; J Michael McWilliams; Christopher P Cannon
Journal:  J Gen Intern Med       Date:  2007-01       Impact factor: 5.128

6.  High Cholesterol Awareness, Treatment, and Control Among Hispanic/Latinos: Results From the Hispanic Community Health Study/Study of Latinos.

Authors:  Carlos J Rodriguez; Jianwen Cai; Katrina Swett; Hector M González; Gregory A Talavera; Lisa M Wruck; Sylvia Wassertheil-Smoller; Donald Lloyd-Jones; Robert Kaplan; Martha L Daviglus
Journal:  J Am Heart Assoc       Date:  2015-06-24       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.